checkAd

     150  0 Kommentare NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors - Seite 2

    “As a luminary in our industry, Roger has an extensive track record leading highly productive teams translating breakthrough science into impactful medicines that treat grievous disease. Given the broad range of Roger’s drug discovery and development expertise, we are honored that Roger has agreed to join the NGM board. His recent experience developing Keytruda is an especially powerful match with NGM’s emerging oncology portfolio,” said Bill Rieflin, Executive Chairman at NGM. “On behalf of our Board, I’d also like to thank David and Mac for their decade of devoted service and intellectual contributions to NGM’s evolution.”

    “I have dedicated my professional career to developing medicines that improve and extend life, and NGM is fundamentally driven by the same motivation,” said Dr. Perlmutter. “In particular, I have long-admired Dr. Jin-Long Chen, with whom I was privileged to work at Amgen, and I am impressed by the way that his ability to elucidate important new biological principles through careful experimentation has enabled NGM to develop a broad pipeline of innovative therapeutic candidates. As a future member of NGM’s board, I look forward to helping to advance NGM’s mission: to deliver transformative medicines to patients.”

    Dr. Perlmutter has served as a director on numerous corporate boards in the U.S. and Europe, and currently serves on the Board of insitro, a privately held machine learning-driven drug discovery and development company.

    Lesen Sie auch

    Prior to assuming leadership roles in the biopharmaceutical industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, Seattle, and also served as Chairman of its Department of Immunology, where he was at the same time an investigator of the Howard Hughes Medical Institute. Dr. Perlmutter was also previously both a Distinguished Fellow and past president of the American Association of Immunologists and is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Dr. Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.

    Seite 2 von 5




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors - Seite 2 SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) - NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today the nomination …

    Schreibe Deinen Kommentar

    Disclaimer